CA2221706A1 - Htnad29 recepteurs de proteines g - Google Patents

Htnad29 recepteurs de proteines g Download PDF

Info

Publication number
CA2221706A1
CA2221706A1 CA002221706A CA2221706A CA2221706A1 CA 2221706 A1 CA2221706 A1 CA 2221706A1 CA 002221706 A CA002221706 A CA 002221706A CA 2221706 A CA2221706 A CA 2221706A CA 2221706 A1 CA2221706 A1 CA 2221706A1
Authority
CA
Canada
Prior art keywords
polypeptide
receptor
polynucleotide
dna
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002221706A
Other languages
English (en)
Inventor
Yi Li
Rebecca A. Fuldner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2221706A1 publication Critical patent/CA2221706A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)

Abstract

L'invention concerne des polypeptides récepteurs du facteur d'activation des plaquettes (PAF) de protéines G humaines, l'ADN (ARN) codant ces polypeptides ainsi qu'une méthode de production de tels polypeptides par des techniques de recombinaison. L'invention concerne également des procédés d'utilisation de ces polypeptides pour l'identification d'antagonistes et d'agonistes de ces polypeptides, ainsi que des procédés d'utilisation thérapeutique de ces agonistes et antagonistes dans le traitement des troubles liés à la sous-expression et à la surexpression des polypeptides récepteurs du facteur PAF. L'invention concerne également des méthodes de diagnostic permettant de déceler une mutation dans les séquences d'acides nucléiques des récepteurs du facteur PAF et permettant de déterminer un niveau de la forme soluble des récepteurs dans un échantillon tiré d'un hôte.
CA002221706A 1995-06-06 1995-06-06 Htnad29 recepteurs de proteines g Abandoned CA2221706A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/007288 WO1996039442A1 (fr) 1995-06-06 1995-06-06 Htnad29 recepteurs de proteines g

Publications (1)

Publication Number Publication Date
CA2221706A1 true CA2221706A1 (fr) 1996-12-12

Family

ID=22249278

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002221706A Abandoned CA2221706A1 (fr) 1995-06-06 1995-06-06 Htnad29 recepteurs de proteines g

Country Status (7)

Country Link
EP (1) EP0832126A4 (fr)
JP (1) JPH11506341A (fr)
KR (1) KR19990022531A (fr)
CN (1) CN1147505C (fr)
AU (1) AU714642B2 (fr)
CA (1) CA2221706A1 (fr)
WO (1) WO1996039442A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221627B1 (en) 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6733990B1 (en) 1999-08-03 2004-05-11 Millennium Pharmaceuticals, Inc. Nucleic acid encoding 15571, a GPCR-like molecule of the secretin-like family
EP2264068A1 (fr) * 1998-10-13 2010-12-22 Arena Pharmaceuticals, Inc. Récepteurs non-endogènes de la protéine G humaine ayant une activité constitutive
US6919176B2 (en) 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
AU2003206749A1 (en) * 2002-02-01 2003-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the gpr65 receptor
MXPA05013721A (es) 2003-06-20 2006-03-08 Novartis Ag Receptores acoplados con proteina-g de deteccion de protones, y secuencias de adn de los mismos.
WO2008101354A1 (fr) * 2007-02-22 2008-08-28 Merck Frosst Canada Ltd Gpr65 utilisé comme cible thérapeutique dans une inflammation allergique des voies respiratoires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
JPH06511386A (ja) * 1991-10-01 1994-12-22 アメリカ合衆国 リガンドおよびリガンドのアンタゴニストを同定する方法
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders

Also Published As

Publication number Publication date
KR19990022531A (ko) 1999-03-25
EP0832126A4 (fr) 2000-01-12
JPH11506341A (ja) 1999-06-08
AU2820495A (en) 1996-12-24
EP0832126A1 (fr) 1998-04-01
CN1147505C (zh) 2004-04-28
CN1193980A (zh) 1998-09-23
WO1996039442A1 (fr) 1996-12-12
AU714642B2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
US20030023044A1 (en) Human G-Protein chemokine receptor (CCR5) HDGNR10
EP1369430A2 (fr) Deux récepteurs couplés par des protéines G: GPCR2 induit par VEB (EBI-2) et GPCR de type GDE-1
US20080241124A1 (en) Human G-Protein Chemokine Receptor (CCR5) HDGNR10
US20050214281A1 (en) G-protein coupled receptor
US5861272A (en) C5A receptor
US20050266527A1 (en) Human G-protein receptor HIBEF51
WO1996039435A1 (fr) Recepteur hpraj70 de proteine g humaine
US20060148708A1 (en) C5a receptor
AU714642B2 (en) G-protein receptor HTNAD29
US20020106740A1 (en) Human G-protein receptor HPRAJ70
US6338951B1 (en) G-protein parathyroid hormone receptor HLTDG74
EP0955808A1 (fr) Recepteur couple de la proteine g humaine
EP1146055A2 (fr) Chemokine recepteur HDGNR10 aux proteines G humaines (recepteur CCR5)
US20050123998A1 (en) C5a receptor
EP1149582A2 (fr) Récepteur humain de Chemokine aux protéines G:HDGNR10 (récepteur CCR5). Ses utilisations.
US20090036398A1 (en) Human G-Protein Coupled Receptor (HETGQ23)
US20050059114A1 (en) G-protein receptor HTNAD29
US20080312178A1 (en) Human G-Protein Receptor HGBER32
CA2220978A1 (fr) Recepteur couple de proteines g humaines (hetgq23)
AU760468B2 (en) G-protein receptor HTNAD29
US20050266522A1 (en) Human amine receptor
US20060014243A1 (en) Human G-protein chemokine receptor HSATU68
US20030054487A1 (en) Human G-protein coupled receptor
US20020106734A1 (en) Adrenergic receptor
CA2221116A1 (fr) Recepteur hltdg74 de l'hormone parathyroidienne (hpt) couple a la proteine g

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead